SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden,

Slides:

Advertisements

Similar presentations

The Cost-Effectiveness of Providing DAFNE to Subgroups of Predicted Responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf of the DAFNE.

Advertisements

Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,

Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.

How Much Improvement in Functional Status Is Considered Important by Patients With Active Psoriatic Arthritis: Applying the Outcome Measures in Rheumatoid.

Remission in Established RA Patients

Complementary and integrative Medicine; George Lewith – Professor of Health Research School for Primary Care Research The.

Real-world effectiveness of nicotine replacement therapy in pregnancy Leonie S. Brose, PhD Andy McEwen, PhD & Robert West, PhD University College London.

Predictors of Cancer-related Pain Improvement over 12 Months Hsiao-Lan Wang, PhD, RN, CMSRN, HFS Assistant Professor University of South Florida September,

Increased exposure to an HIV risk reduction protocol associated with a reduction in drug abuse severity Louise F. Haynes 1 ; Rickey E. Carter 1 ; Amy E.

Socio-economic inequalities in the pathway of care for pancreatic cancer James Brown, Jean Adams, Martin White & Mark Pearce Institute of Health & Society.

Infectious arthritis Bacterial Viral Other Postinfectious (reactive) arthritis Rheumatic fever Reactive arthritis Enteric infection Other seronegative.

SARAH: Strengthening and Stretching for Rheumatoid Arthritis Affecting the Hand: A randomised controlled trial Adams J, Williams MA, Heine PJ, McConkey.

IMAGING NEURAL CORRELATES OF FATIGUE & PAIN IN PATIENTS WITH RA TREATED WITH TNF INHIBITORS FARHAN BARI SPR RHEUMATOLOGY WARN CONFERENCE 22 ND MAY 2014.

Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.

Implementation of a lung health clinic in high-risk individuals in South East London: a prospective feasibility cohort study Background In 2013, lung cancer.

J Browne, DA Edwards, KM Rhodes, DJ Brimicombe, RA Payne

A NEW LOOK AT RA Interactive Hot Topics Series

Sofija Zagarins1, PhD, Garry Welch1, PhD, Jane Garb2, MS

Fibromyalgia Impact Questionnaire McGill Pain Questionnaire

Jonathan Foulds, Jessica M. Yingst, Susan Veldheer, Shari Hrabovsky,

Anti-TNF therapy improves hand function in rheumatoid arthritis

LONG TERM DRUG-FREE CLINICAL-REMISSION IN PATIENTS WITH RA ON cDMARDs

Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1

The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy

Vibeke Strand, MD, MACR, Jasvinder A. Singh, MD, MPH

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Rhematoid Rthritis Respiratory disorders

Decision-making in the eRA of Treating to Target

1. Bristol Medical School, University of Bristol

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Clinical and patient-reported outcomes for patients randomised to CZP 200 mg Q2W and CZP 400 mg Q4W to week 96. Clinical and patient-reported outcomes.

Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

OR for selected baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by multivariate analysis of observed data. OR for selected baseline predictors.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

Mean differences with 95% CI between the Internal Family Systems (IFS) intervention group and the education group in study outcomes at baseline and 3,

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Patient-reported outcomes: proportion of patients with clinically meaningful improvements in (A) SF-36 PCS and MCS at Week 52 and Week 104*†‡ and (B) HAQ-DI.

Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.

2017/18 National Diabetes Audit Cambridgeshire and Peterborough CCG local summary Public Health Intelligence, Cambridgeshire and Peterborough : April 2019.

Independent baseline predictors of non-remission at 24 months of follow-up in the SWEFOT trial population. Independent baseline predictors of non-remission.

Evaluating the Effectiveness of a Primary Mental Health Care Service on Outcomes for Common Mental Disorders: Modelling the Effect of Deprivation Jonathan.

Clinical response in patients with early and established RA at month 24. *p

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) and number needed to treat (NNT) in (A) patient-reported.

Percentage of patients with RA achieving DAS28(CRP)<2

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Mean Short-Form 36 (SF-36) domain scores at baseline and 6 months in patients receiving active or placebo corticosteroids, cDMARDs or TNFis. Mean Short-Form.

Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

(A) JIA-ACR30/50/70/90 response rates by visit in part 1.

Multivariable model of adjusted

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Socioeconomic status variations in asthma outcomes in England, standardised event ratios by Index of Multiple Deprivation (IMD; 1 is least deprived), sex.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Stacked bar charts for key predictor variables (representativeness of SLS COPD). Stacked bar charts for key predictor variables (representativeness of.

Presentation transcript:

SAT0699 Rapid assessment predicts disease activity improvement in newly diagnosed Rheumatoid Arthritis (RA) Mark Yates*, James Galloway, Neil Snowden, Sam Norton, Jo Ledingham, Elaine Dennison, Ali Rivett, Andrew Rutherford, Alexander Macgregor. *mark.yates@kcl.ac.uk, Academic Rheumatology Dept, King’s College London, UK Introduction Early intervention in RA is associated with improved outcomes in randomised trials (1). UK guidelines for review of suspected early inflammatory arthritis recommend that; There are limited real world data confirming the value of early assessment. Previous work suggests social deprivation predicts severe disease at presentation and a worse clinical course (2). The impact of deprivation in early assessment has yet to be characterised on a national level. Figure 1. Most deprived area 1st 32,844th Least deprived area The Index of Multiple Deprivation (IMD) A ranking of each small area in England… …Based on 7 domains Results A total of 5622 RA diagnosed patients recruited across England and Wales. 39.7% (n= 2234) provided DAS-28 baseline and follow up data. 16% (n=901) provided RAID baseline and follow up data. Early rheumatology assessment associates with achieving a good EULAR response and MCID RAID. Unit level variation is very high. “People with suspected persistent synovitis are assessed in a rheumatology service within 3 weeks of referral” Timely rheumatology assessment associates with: A good EULAR DAS-28 response (adj OR 1.38 (CI1.15-1.66)) RAID improvement (adj OR 1.44 (CI1.03-2.02)) Discussion Timely rheumatology review leads to improved outcomes, seen as early as 3 months. Amongst those who were assessed within 3 weeks of referral, an additional 8% achieved a good EULAR DAS-28 response. Those who are more deprived have a weaker association between early review and the patient reported RAID score. Missing data are an issue. Imputation is proposed. Methods A prospective longitudinal observational study of early RA care in England and Wales. Clinician and patient questionnaire at baseline and through to 3 months follow up. Predictor variable: Rheumatology assessment within 3 weeks. Outcome variables: EULAR DAS-28 good response, meaningful improvement in RAID score. Confounders: IMD quintile (see figure 1), age, gender, smoking status, ethnicity. Primary analysis is multivariate logistic regression. Seen within 3 weeks Not seen within 3 weeks P Value N 878 1356 Age (SD) 58.6 (14.8) 59.9 (14.1) 0.046 * Female % 65.2 64.4 0.24 ** White British % 86 88.9 0.015 ** Current smoker % 21.1 25.4 0.009 ** IMD quintile mean 3 DAS28 EULAR good response % 43.7 35.8 0.001 ** Achieved MCID† RAID % 48 40.7 0.026 * *t-test **chi-squared †Minimal clinically important difference (reduction by 50% or absolute reduction >3) Acknowledgements Many thanks to The British Society for Rheumatology for funding this work, and all staff in the Academic Rheumatology Dept at King’s College London for support and advice. RA Impact of disease (RAID) score A patient reported outcome measure focussing on 7 domains: pain, functional disability, fatigue, sleep, physical wellbeing, emotional wellbeing, and coping. References Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004 Jul 17-23;364(9430):263-9. ERAS Study Group. Socioeconomic deprivation and rheumatoid disease: What lessons for the health service? Ann rheum dis. 2000;59(10):794-9.